Quest Publishes Validation Study of HIV Tropism Test Combining 454 and Sanger Sequencing | GenomeWeb

Quest Diagnostics has published a validation study of its laboratory-developed HIV tropism test that uses a combination of Sanger sequencing and next-generation sequencing on Roche's 454 GS Junior platform.

Quest began offering the test this summer for patients with HIV to determine whether they are eligible to receive the drug maroviroc, marketed by Pfizer as Selzentry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.